Selective targeting of an intact FA/BRCA2 pathway is an emerging approach to cancer therapy.25, 26, 27, 28 Several FA pathway inhibitors have been developed and shown to be successful in addressing cisplatin resistance.29, 30 Although more development is required, FA targeting clearly represents a potential clinical strategy. Here, FANCA is linked to cancer.